Pace Napoleone Carlo, Condello Ignazio, Cascarano Maria Teresa, Aidala Enrico, Peruzzi Licia, Molinari Isabella, Rivoldini Cristina, Di Carlo Maria Stella, Iannandrea Stefania, Bonaveglio Enrico
Department of Pediatric and Congenital Cardiac Surgery, Regina Margherita Children's Hospital, 10024 Torino, Italy.
Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, Via Camillo Rosalba 35/37, 70124 Bari, Italy.
Medicina (Kaunas). 2025 Mar 13;61(3):493. doi: 10.3390/medicina61030493.
: Pediatric ECMO is a valid support mechanism for refractory cardiac and/or respiratory failure. Magnetic levitation technology applied to the centrifugal pump has reduced the hemolysis caused by this procedure, which can be particularly dangerous, especially in neonates and small children. ECMOLife, a new magnetic levitation centrifugal pump, has been introduced for these patients. : Four patients were supported with the ECMOLife System in a newborn setting, with veno-venous application in two cases and veno-arterial in the other two. All parameters related to pump functioning, anticoagulation, hemolysis, and inflammation were recorded for the duration of the support. : All patients survived the procedure, in three cases achieving recovery, while one veno-arterial ECMO was switched to VAD, and then the patient underwent heart transplantation. All recorded parameters were compatible with clinical conditions. In particular, free haemoglobin was close to 0 g/L in all recorded samples. The possibility of monitoring pump functioning parameters, venous and arterial O2 saturation, and venous and arterial pressures creates an opportunity to check the adequacy of mechanical support for the clinical condition of the patient. : This is the first reported experiment in a newborn setting with ECMOLife mechanical support. At present, ECMOLife represents the only system with a newborn and pediatric pump, allowing for the continuous monitoring of perfusion and hemodynamic parameters, with a large number of facilities for transportation available.
小儿体外膜肺氧合（ECMO）是治疗难治性心脏和/或呼吸衰竭的一种有效支持手段。应用于离心泵的磁悬浮技术减少了该操作引起的溶血，而溶血可能特别危险，尤其是在新生儿和小儿中。已为这些患者引入了一种新型磁悬浮离心泵ECMOLife。在新生儿环境中，有4例患者接受了ECMOLife系统支持，其中2例采用静脉-静脉模式，另外2例采用静脉-动脉模式。在支持期间记录了所有与泵功能、抗凝、溶血和炎症相关的参数。所有患者均成功完成该操作，3例实现康复，1例静脉-动脉ECMO转为心室辅助装置（VAD），随后该患者接受了心脏移植。所有记录的参数均与临床情况相符。特别是，所有记录样本中的游离血红蛋白均接近0 g/L。监测泵功能参数、静脉和动脉血氧饱和度以及静脉和动脉压力的可能性为检查机械支持对患者临床状况的充分性创造了机会。这是首次报道在新生儿环境中使用ECMOLife进行机械支持的实验。目前，ECMOLife是唯一一款配备新生儿和小儿泵的系统，能够持续监测灌注和血流动力学参数，并且有大量可用的运输设备。
